Integrated Screening Cascades for Ion-Channel Drug Discovery: Linking Structure, Electrophysiology, Safety Pharmacology, and Human-Relevant Models

Figures

• 

  Figure 4. Qualitative evidence map of ion-channel discovery platforms. Platforms are positioned according to two conceptual axes: throughput/scalability and mechanistic resolution. Bubble size represents approximate translational relevance, defined by the extent to which a platform captures disease-relevant cellular context, safety-relevant physiology, or human tissue complexity. The map is intended as a heuristic framework rather than a quantitative ranking system. Its purpose is to illustrate complementarity among platforms: high-throughput approaches are efficient for front-end discovery, electrophysiological methods provide direct mechanistic confirmation, safety panels reduce attrition risk, and organoid/MPS or in vivo models increase translational confidence. The key message is staged evidence accumulation, not single-platform superiority. Practical criteria for distinguishing acute channel inhibition from protein-level channel remodeling are summarized in Table 6.

• 

  Figure 1. Ion channel network remodeling across cell types. Pathophysiological communication among tumor cells, immune cells, fibroblasts, epithelial barriers, and stromal compartments is organized around TRP, Kv, Piezo, and chloride-channel signaling. The schematic highlights how inflammatory cytokines, mechanical stress, hypoxia/acidosis, growth factors, and extracellular matrix remodeling reshape multicellular ion channel networks in tumor-inflammatory microenvironments.

• 

  Figure 2. Hybrid screening cascade workflow for ion-channel drug discovery. The workflow integrates artificial intelligence (AI)-assisted virtual screening, optical high-throughput screening (HTS), automated patch-clamp (APC) electrophysiology, safety and counter-screening, organoid or three-dimensional translational models, and preclinical transition. Each stage contributes a distinct decision layer. AI-assisted triage prioritizes plausible and developable chemotypes; optical HTS identifies scalable functional activity while excluding assay-interference artifacts; APC confirms direct current modulation, kinetic behavior, reversibility, and state-dependent pharmacology; safety profiling evaluates hERG/Kv11.1, voltage-gated sodium channel Nav1.5, voltage-gated calcium (Cav) channels, cytotoxicity, and off-target liabilities; organoid and microphysiological system (MPS) models test whether the mechanism retains relevance in human-like disease contexts; and preclinical transition integrates pharmacokinetics/pharmacodynamics (PK/PD), efficacy, safety, target engagement, and candidate-readiness criteria. Feedback loops indicate that safety liabilities may redirect medicinal chemistry, APC…

• 

  Figure 3. State-dependent ion-channel pharmacology. Ion channels cycle among resting, open, and inactivated conformations. Ligands may preferentially stabilize specific states, producing resting-state inhibition, open-state block, inactivated-state inhibition, use dependence, kinetic trapping, and disease-state selectivity. Examples include use-dependent sodium-channel block by local anesthetics or antiarrhythmic agents, as well as protocol-dependent modulation of potassium and calcium channels. These properties explain why voltage protocols and kinetic analyses are central to ion-channel pharmacology. Colors indicate state classes and corresponding inhibitor types: purple, resting/closed state; orange, open/conducting state; and green, inactivated state.